Y Glipt M 500mg/20mg Tablet ER is a combination oral antidiabetic medication containing Metformin hydrochloride 500mg and Teneligliptin 20mg, formulated for extended release. Metformin is a biguanide that primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels, which inhibit glucagon release, increase insulin secretion, and decrease gastric emptying, contributing to improved postprandial and fasting blood glucose levels. This combination is indicated for the management of type 2 diabetes mellitus in adults when diet and exercise alone do not provide adequate glycemic control. The extended-release formulation allows for once-daily dosing, improving patient compliance. Y Glipt M should be used with caution in patients with renal impairment, hepatic dysfunction, or a history of lactic acidosis. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. Regular monitoring of blood glucose levels and renal function tests is recommended during therapy. This combination therapy offers a complementary mechanism of action targeting multiple pathophysiological defects in type 2 diabetes, optimizing glycemic control.